Direct answer
Small, varied astaxanthin trials report skin moisture and elasticity signals, but clinical meaning and certainty are limited. Wrinkle depth was not significantly different, and a manufacturer-funded UV trial did not establish sunscreen protection. A newer exercise review reports mixed outcome signals with reporting limitations; recovery enzymes do not prove faster functional recovery. The cited studies do not demonstrate human lifespan extension or universal safety. US food notices and EU/GB conditions are ingredient-specific, and some source funding, backing and product terms remain unknown.
- Astaxanthin is a reddish-orange carotenoid. Skin trials used specified preparations, often derived from Haematococcus pluvialis; their protocols do not establish an optimal retail dose or equivalence of algal, krill, yeast and synthetic sources (skin review; production review).
- Zhou’s review discussed 11 publications and identified nine oral RCTs; eight RCTs were pooled. Moisture (SMD 0.53; 95% CI 0.05–1.01) and elasticity (0.77; 0.19–1.35) favoured treatment, while wrinkle depth was not significantly different. Small heterogeneous trials, combination products and unclear bias limit certainty and clinical meaning (original Methods/Results).
- A historical seven-RCT review (280 participants; search through November 2014) found no significant primary pooled lipid or glucose effects. A bias-adjusted glucose sensitivity analysis was positive; neither result establishes diabetes treatment or every later study’s outcome (original Results).
- The cited “geroprotector” review discusses cell/animal mechanisms and some human functional observations. Those observations do not establish human lifespan extension or a validated general anti-aging effect (reviewed clinical/mechanism sections).
- US food-use notices are ingredient- and use-specific: GRN 580 concerns algal extract, while GRN 700 concerns a bacterial mixed-carotenoid extract. FDA “no questions” is not universal product approval. EFSA’s ADI is 0.2 mg/kg/day from total exposure; EU supplement rules have age-specific amounts, rather than one dose for all children (GRN 580 inventory; GRN 700 original; EFSA 2020; EU rule).
- Evidence appraisal: Limited certainty for skin moisture/elasticity, historical primary null findings for lipids/glucose, and no demonstrated human lifespan extension in the sources discussed. Selected safety reports and regulatory conditions do not establish every product’s safety.
Table of contents
- Evidence summary
- What astaxanthin is
- Preparations and sources
- Proposed mechanisms
- Claims and evidence limits
- Benefits by claim
- Claims and limits
- Safety findings and gaps
- Medicines and evidence gaps
- Who should seek advice first
- Studied doses and regional rules
- How nonclinical evidence is used
- Funding, conflicts and source roles
- Frequently asked questions
- Sources and funding notes
| Claim | Evidence | Source | Funding/conflict | Strength |
|---|---|---|---|---|
| Skin moisture | Five pooled studies: SMD 0.53 (0.05–1.01); I² 52% | Zhou original | Hunan support acknowledged; authors report no study funds and no conflicts. Underlying finances not all traced | Limited certainty; not proven perceptible cosmetic benefit |
| Skin elasticity | Six pooled trials: SMD 0.77 (0.19–1.35); I² 75% | Zhou original | Small varied trials, including combination preparations and commercial products | Limited certainty; substantial inconsistency |
| Wrinkle depth | No significant difference: SMD −0.26 (−0.58 to 0.06) | Zhou original | Review declarations do not establish every trial’s independence | Limited precision; not proof of no possible effect |
| Lipid changes | No significant primary pooled effect across seven RCTs/280 participants; search through November 2014 | Ursoniu original | Review reports no support or conflicts; included-trial financing not all traced | Historical null; not a current all-study census |
| Fasting glucose | Primary estimate null; exploratory trim-and-fill adjustment favoured lower glucose | Ursoniu original | Review disclosure differs from underlying-trial finance | No established diabetes-treatment benefit |
| UV-related skin response | Small selected UV-response and hydration studies; no measured SPF or skin-cancer prevention | Ito original; skin review | Ito: FUJIFILM sponsor/funder and employee authors; review does not establish every underlying trial’s finances | Limited, endpoint-specific evidence |
| Human lifespan extension | Not demonstrated by the cited narrative review; some human functional observations are discussed | 2020 review | NIA writing support; Cardax advisory/consultant role; Solgar assistance | Mechanistic hypotheses and function measures are not lifespan proof |
| Exercise performance and recovery | A 2026 review reports null performance pools and CK/LDH biomarker signals; mixed protocols and reporting inconsistencies limit confidence | original review | Joint laboratory and named grants; no conflicts declared; complete backing unknown | Not reliable universal performance or functional-recovery proof |
| US ingredient-specific food use | GRN 580 algal extract: specified foods at 0.15 mg/serving. GRN 700 is a different bacterial mixed extract | GRN 580 inventory; GRN 700 | Company-submitted notices assessed by FDA | No questions is not a universal approval or efficacy finding |
| EFSA adult exposure assessment | 8 mg supplement plus high background diet below ADI in the modeled 70 kg adult; children modeled at the same dose can exceed it | EFSA original | Stakeholder/industry dossiers evaluated by regulator; individual disclosures not independently traced | Specific total-exposure model, not personal-dose or all-product clearance |
What astaxanthin is
Astaxanthin is a red-orange xanthophyll found in algae and other microorganisms and accumulated in some seafood (review background). H. pluvialis can accumulate substantial pigment under stress; the 2023 food paper cites up to about 6% dry weight in its background and analyses astaxanthin-rich wet paste in pancakes. That is composition research, not a human skin trial (original food experiment). The GB assessment describes a specified oleoresin production process, not every manufacturer’s extraction method (FSA/FSS assessment). The clinical questions here concern skin measurements, UV response, cardiometabolic measures, exercise and longevity claims.
Preparations and sources
Sources and processing can change composition. Ingredient identity, preparation and actual milligrams matter; similar labels do not establish identical trial outcomes or a superior form.
| Preparation | Source/processing | Composition context | Evidence boundary |
|---|---|---|---|
| Algal oleoresin | Cultivated H. pluvialis; extraction/process depends on the assessed preparation | FSA/FSS assessed a 2.9–11.1% astaxanthin oleoresin specification | A specified regulatory ingredient, not every product or an all-trial census (original specification) |
| Krill-derived pigment | Krill oil contains astaxanthin alongside omega-3 lipids | The review describes omega-3 phospholipids separately; no universal pigment dose per serving verified | Do not equate krill oil or its phospholipid content with an isolated astaxanthin trial (composition review) |
| Synthetic astaxanthin | Chemical production can yield a different stereoisomer mixture | The 2016 review discusses extensive feed use; that is historical context | No current market share or natural-versus-synthetic clinical superiority follows (production review) |
| Yeast-derived astaxanthin | Xanthophyllomyces dendrorhous, formerly Phaffia rhodozyma | Another biosynthetic source discussed in the production review | Source identity is not proof of present market share, efficacy or interchangeable dose (review) |
Proposed mechanisms
Astaxanthin’s lipid-soluble structure and cell/animal antioxidant observations suggest mechanisms; they do not establish clinical superiority to other antioxidants. Zhou discusses absorption with food and proposed skin pathways, but did not measure the proposed mechanism as a causal explanation of pooled cosmetic effects (original Discussion). The geroprotector review describes biochemical and animal hypotheses and some human functional studies; none demonstrates human lifespan extension (reviewed sections).
Claims and evidence limits
Claims about skin hydration, “internal sunscreen”, exercise recovery and longevity require different outcomes. A changed skin instrument reading, a laboratory biomarker or an animal pathway does not by itself show sun protection, faster functional recovery or longer human life.
- Skin and sunscreen: Zhou pooled eight RCTs from a wider review of 11 publications. Moisture and elasticity favoured treatment, but wrinkle depth did not differ significantly; imputed variability, inconsistent protocols, combination products and mostly small trials limit certainty (Methods/Results/Discussion). These measured parameters do not establish a clinically noticeable cosmetic benefit or sunscreen protection. The review acknowledges Hunan project support while declaring no funds received by authors and no conflicts; underlying-trial finances are not all traced.
- Lipids and glucose: Ursoniu’s seven-RCT synthesis searched through November 2014 and had null primary lipid/glucose pools, but a glucose bias-adjustment sensitivity estimate was significant (original Results). Its small varied studies do not establish diabetes treatment, equivalence to no effect or the outcome of all later cardiometabolic research.
- Longevity: The cited review includes human cognitive/functional observations and combinations, alongside extensive animal/cell work. Those endpoints do not establish longer human life or a general reduction in age-related disease; a laboratory longevity pathway is insufficient (clinical/mechanism review).
The reviewed skin measurements are promising but uncertain. The UV trial did not establish an SPF, the historical lipid/glucose review is not a current literature census, and narrative functional observations do not prove lifespan extension (skin review; UV trial; historical meta-analysis; longevity review).
Benefits by claim
Skin moisture and elasticity
Zhou reviewed 11 publications, identified nine oral RCTs and pooled eight RCTs (162 active and 131 control participants). Moisture pooled five studies (SMD 0.53; 95% CI 0.05–1.01; I² 52%), elasticity six (0.77; 0.19–1.35; I² 75%), and wrinkle depth was not significant (−0.26; −0.58 to 0.06). Some preparations combined 2 mg astaxanthin with tocotrienol or fish collagen, and one comparator was active rosehip powder. Graph-digitized data, imputed variability, unclear bias and different measurement sites/seasons weaken causal and practical interpretation (complete relevant original). Standardized effects are not a percentage improvement or proof users notice a cosmetic difference. Its acknowledgements name Hunan projects; authors separately report no study funds and no conflicts. Those statements do not trace every trial’s support or establish financial independence.
UV-induced skin deterioration ("internal sunscreen" claim)
Ito randomized 23 healthy Japanese adults and analysed 22 per protocol after nine weeks of 4 mg/day ASTOTS. One active participant with aberrant bilirubin before and after supplementation was excluded; causality was not established. Minimal-erythema-dose change favoured treatment, while the raw post-treatment comparison was not significant (p=0.162). All three authors were FUJIFILM employees and the company sponsor/funder, despite “no external funding.” The small selected trial reports no adverse events; it did not establish an SPF, skin-cancer prevention or sunscreen replacement (original Methods/Results/disclosures).
Lipids and glucose
Ursoniu’s 2015 synthesis included seven RCTs/280 people, 4–20 mg/day over four weeks to three months, with a search through November 2014. Primary lipid and glucose pools were not significant. An exploratory trim-and-fill glucose estimate became significant after imputing potentially missing studies; this is not an observed new trial or established diabetes-treatment benefit (original Methods/Results). Authors declared no financial support or conflicts. Modest samples, diverse populations and possible small-study bias limit confidence, and underlying-trial finances were not all traced.
Endurance and exercise performance
A 2026 review identifies 24 RCTs and reports no significant pooled improvement in VO₂max, time-trial performance or maximal workload/power. It reports favourable CK and LDH biomarker pools, but LDH lost significance after omitting one study. These enzymes do not directly measure functional recovery. Mixed formulations/co-interventions, small outcome pools and reporting inconsistencies limit confidence: its VO₂ pooling cites studies whose own Table 1 says VO₂ was measured only at baseline, and its time-trial sensitivity cites a walking/training combination study. The review lists Peking University Medical–Qingyan Boshi Joint Laboratory and other grant support, with no competing interests declared; its full backing and all underlying trial finances are unknown (original Methods/Results/disclosures). This is uncertain, outcome-specific evidence, not a reliable universal performance or recovery recommendation.
"Geroprotector" / longevity
The cited geroneuroprotection review discusses lifespan-related pathways in cells/animals and human cognitive or functional observations, sometimes with combinations. It does not demonstrate that astaxanthin extends human lifespan or broadly prevents age-related disease. B.J. Willcox reports NIA writing-time support and a Cardax consultant/advisory-board role; Solgar assistance is acknowledged (original relevant sections/declarations). These relationships and endpoint limits constrain interpretation.
Claims and limits
| Claim | Verdict | Evidence basis |
|---|---|---|
| Skin moisture | Positive pooled instrument measurement; limited certainty | Five studies in the eight-RCT quantitative review; not proof of noticeable benefit (original) |
| Skin elasticity | Positive pooled measurement; substantial heterogeneity | Six trials, I² 75%; combinations and measurement differences limit interpretation (original) |
| Wrinkle depth | No significant pooled difference | Imprecise null does not establish no possible effect (original) |
| Sunscreen replacement | Not established by these studies | Skin readings and a small UV-response trial do not establish SPF or cancer prevention (review; UV trial) |
| Cholesterol/LDL/triglycerides | Historical primary pooled null | Seven RCTs/280 people; search through November 2014, not all later studies (original) |
| Glucose treatment | Not established by this synthesis | Primary pool null; exploratory imputed-study adjustment positive, not diabetes-treatment proof (original) |
| Human lifespan extension | Not demonstrated by the cited review | Functional observations and laboratory pathways are distinct from longer human life (original review) |
| Exercise performance / recovery | Uncertain and outcome-specific | 2026 review reports null performance pools and enzyme signals, with formulation/reporting limitations; biomarkers are not functional recovery (original) |
Safety findings and gaps
| Safety question | Observed evidence and limits | Source |
|---|---|---|
| Selected UV-trial adverse events | Ito reports no adverse events in 22 analysed selected adults over nine weeks; rare harms and all-product risk cannot be estimated | original Results |
| Digestive or pigment-change frequency | The skin meta-analysis did not provide a systematic pooled adverse-event frequency; it cannot establish “occasional”, universally mild or harmless events | review Methods/Results |
| Short-term regulatory trial data | Provided studies used 2–40 mg/day for ten days to three months without important measured adverse changes; insufficient for long-term clearance | EFSA human-study assessment |
| Modeled childhood ADI exceedance | EFSA 2020 assumed 8 mg supplement daily at every age, plus high background diet: 10–14-year estimate 28% above ADI; 4–6-month infants up to 524% above. Not typical infant use or observed harm | original exposure model |
| Pregnancy/lactation and children | Not established by the selected human studies; Ito excluded pregnancy and EFSA 2014 noted absence of these groups in supplied clinical studies | eligibility; clinical assessment |
Short selected trials and regulatory summaries cannot rule out rare harms or establish every product’s long-term safety. Ito reported no adverse events in its analysed sample, while EFSA 2014 emphasised short human follow-up and population gaps (trial; assessment). EFSA 2020’s childhood concern is a total-exposure model assuming 8 mg supplements, not an observed harm rate or typical infant use (model).
Medicines and evidence gaps
| Medicine/context | What the cited evidence measures | Practical boundary | Evidence basis |
|---|---|---|---|
| Blood-pressure medicines | The skin/UV protocols are not dedicated interaction studies | No quantified additive-hypotension risk or combination safety follows from these outcomes | Ito excluded regular medicines and selected healthy participants (Methods) |
| Glucose-lowering medicines | Historical glucose outcomes, including sensitivity analyses; not medicine-specific pharmacokinetics/hypoglycaemia rates | Do not treat a pooled glucose trend as a measured interaction or alter diabetes treatment on this basis | original endpoints |
| Other antioxidant combinations | Some skin protocols combined astaxanthin with tocotrienol or fish collagen | Those specific combinations do not prove every high-dose antioxidant mixture safe, beneficial or harmful | original trial table |
| Medicines metabolised by CYP enzymes and other combinations | Cultured human hepatocytes showed CYP3A4/CYP2B6 induction at 3.75 μM, not 0.375 μM; clinical relevance unresolved | Laboratory mechanism does not quantify interaction with any specific drug or establish every combination’s safety | original CYP assessment |
Who should seek advice first
- Pregnancy or breastfeeding: seek individual advice; the selected studies do not establish safety and Ito excluded pregnancy (Methods; human-study assessment).
- Children: do not extrapolate an adult dose. EU conditions set lower age-specific amounts and exclude use under three; EFSA’s 8 mg-at-every-age model is a different scenario (binding Annex; model).
- Regular medicines: review the exact combination with a clinician or pharmacist. The selected trials and cultured-cell data do not quantify medicine-specific clinical risks or prove safety (selected protocol; CYP assessment).
- Sun protection or cardiometabolic treatment: these outcomes do not establish sunscreen replacement or an effective substitute for clinical lipid/glucose care (UV outcomes; historical metabolic review).
- Known food allergy: check the source and other ingredients. Krill is a crustacean source, and FDA identifies crustacean proteins among major food allergens. A refining method or astaxanthin label alone cannot establish your specific product’s allergen content or personal safety (krill composition; allergen guidance).
Studied doses and regional rules
| Parameter | Value | Source |
|---|---|---|
| Skin-study protocols | Astaxanthin 2–12 mg/day across oral protocols, sometimes in combinations; four to 16 weeks | Study amounts do not establish an optimal retail dose (original Table 1) |
| Historical US NDI reporting | Trade press reports AstaReal 2012 no-objection correspondence at 12 mg/day; original response not recovered here | Product-specific secondary reporting, not universal FDA-approved dose (historical reporting; official notification process) |
| EFSA total-exposure ADI | 0.2 mg/kg body weight/day | Applies to total astaxanthin exposure, not an individual supplement prescription (original assessment) |
| EU and Great Britain differ | EU 2023 Annex: 2.3 mg/day age 3 to under 10; 5.7 mg/day 10 to under 14; 8 mg/day population older than 14. GB RP2213 assesses 8 mg/day age 14 and over | EU legal conditions and age/same-day labels are distinct from the GB specification-change safety opinion (EU rule; GB assessment) |
| EFSA 2020 modeled age exposure | Assumed 8 mg/day supplement plus high background diet at every age; children/infants exceeded ADI, adolescents approximately reached it | Not a typical infant-use or observed adverse-event estimate (original model) |
| Absorption guidance | Lipid-soluble; food containing fat may improve absorption | Zhou 2021, Nutrients (bioavailability discussion) |
| Preparation and dose equivalence | Some 2 mg protocols included tocotrienol or fish collagen; other astaxanthin protocols used 4–12 mg | Eight RCTs pooled; not every preparation isolated pigment or inert-placebo comparison (original Methods/Table 1) |
How nonclinical evidence is used
Human trials provide clinical endpoints; cell/animal studies can inform hypotheses and regulatory safety assessments. Each type of evidence has a distinct role and cannot establish every clinical benefit, safety outcome or financial relationship.
- Longevity pathways: the review discusses animal lifespan and cell mechanisms as well as some human functional studies. None of the discussed human endpoints establishes longer lifespan; cultured human cells remain nonclinical experiments (reviewed original sections).
Regulatory safety uses nonclinical evidence too: EFSA’s ADI incorporates rat data, and its CYP discussion includes cultured human hepatocytes. Those observations do not directly quantify human clinical benefit or a particular medication interaction (ADI derivation; CYP assessment).
Funding, conflicts and source roles
Research funding at a glance
7 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | Declared support / relationships | Role and remaining limits |
|---|---|---|
| Zhou 2021 skin review | Hunan 2017TP1021/2020NK2020 acknowledged; Funding says authors received no funds; no conflicts declared | Both declarations retained. Complete trial support/procurement and grant allocation not traced (original declarations) |
| Ursoniu 2015 metabolic review | No financial support from any company/institution and no conflicts declared | Review-level declarations do not establish financing of all included trials (original declaration) |
| EFSA 2020 | Regulatory opinion using stakeholder dossiers, including AstaReal-related submissions | Individual panel forms and all underlying study finances not independently checked; not an efficacy trial (source dossier list) |
| EFSA 2014 AstaReal assessment | BioReal/AstaReal submitted the dossier | Industry-origin data assessed by regulator; proprietary records and all financial chains not independently recovered (original assessment) |
| FDA GRN 700 | JX Nippon bacterial mixed-carotenoid notice | Company-submitted safety conclusion; FDA no questions under specified uses, not approval of all algal supplements (original response) |
| Nutritional Outlook NDI report | Historical trade journalism quoting AstaReal/supplier statements | Original product-specific FDA response and article-specific financial influence not independently recovered (article) |
| 2020 geroneuroprotector review / 2026 exercise review | 2020: NIA writing-time support, Cardax advisory/consultant role and Solgar assistance. 2026: Peking University Medical–Qingyan Boshi Joint Laboratory and other named grants; no competing interests declared | Ultimate backing, grant amounts and underlying-trial finances not fully traced (2020 declarations; 2026 declarations) |
Frequently asked questions
Does astaxanthin really work as an "internal sunscreen"?
The discussed studies do not establish sunscreen replacement. Zhou’s small varied skin trials reported moisture/elasticity signals but an imprecise wrinkle-depth null; Ito’s manufacturer-funded UV experiment found a change-score signal without a significant raw post-treatment comparison. Neither established an SPF or skin-cancer prevention (review; original UV trial).
Does astaxanthin lower cholesterol or blood sugar?
The historical seven-RCT review searched through November 2014 and found null primary lipid/glucose pools. A glucose sensitivity analysis using imputed missing studies was positive; this is not an observed new trial or established diabetes treatment. These findings cannot establish all later studies’ outcomes or replace prescribed care (original Results).
Is astaxanthin a proven longevity supplement or "geroprotector"?
The cited review does not demonstrate human lifespan extension. It includes some human cognitive/functional observations and combinations, alongside animal/cell pathways; function or a mechanism is not the same as longer life or a general anti-aging benefit (relevant original review).
What is the difference between natural, krill-derived, and synthetic astaxanthin?
Algal, krill, yeast and synthetic sources can differ in preparation and composition. The production review describes historical uses, not today’s complete market or trial census (2016 review). Krill oil contains other lipids, so its effects cannot be assigned automatically to isolated astaxanthin (composition review). The particular skin-study materials also varied (trial table); source names alone do not establish clinical superiority.
How much astaxanthin is safe to take daily?
There is no single personal dose established for every product or age. EFSA 2020 modeled 8 mg supplements plus background diet below the 0.2 mg/kg/day ADI for a 70 kg adult; that benchmark concerns total exposure. EU 2023 rules set 2.3 mg/day for age 3 to under 10, 5.7 mg/day for 10 to under 14 and 8 mg/day for people older than 14, with age and same-day supplement restrictions. Those conditions are distinct from product-specific historical US NDI reporting and the GB assessment (EFSA model; EU Annex; attributed US report; GB assessment).
Is astaxanthin regulated as GRAS in the US?
FDA’s GRN 580 inventory concerns INNOBIO algal astaxanthin-ester extract in specified foods at 0.15 mg/serving, with a no-questions response. GRN 700 concerns JX Nippon’s bacterial mixed extract. FDA’s letter does not affirm GRAS for every product or establish clinical efficacy; GRAS food-use notices and supplement NDI notifications are distinct processes (GRN 580; GRN 700 original; NDI explanation).
Sources and funding notes
- Zhou 2021 skin meta-analysis — Eleven publications discussed; eight RCTs pooled. Hunan support acknowledged alongside no author study funds/no conflicts declarations. Underlying-trial support and combinations remain relevant.
- Ursoniu 2015 metabolic meta-analysis — Search through November 2014; primary lipid/glucose pools null, exploratory glucose bias adjustment positive. No review support or conflicts declared; not a complete underlying-trial finance assessment.
- 2020 geroneuroprotector review — Narrative clinical/mechanism background, not human lifespan proof. NIA writing support, Cardax advisory/consultant role and Solgar assistance disclosed.
- EFSA 2020 supplement assessment — Regulatory total-exposure model and updated ADI, using stakeholder data; not typical infant use, efficacy or every-product clearance.
- EFSA 2014 AstaReal assessment — BioReal/AstaReal dossier; short human-study summaries and nonclinical safety/CYP data. Individual disclosures and every underlying original not independently traced.
- FSA/FSS RP2213 assessment — Great Britain specification-change safety opinion concerning an AstaReal application; assessed oleoresin 2.9–11.1%. Not itself a universal UK/EU authorization.
- Commission Implementing Regulation (EU) 2023/1581 — Original age-specific supplement Annex and required labels, with ingredient-specific legal conditions.
- FDA GRN 000700 response — JX Nippon bacterial mixed-carotenoid extracts from Paracoccus carotinifaciens; specific uses and no-questions scope.
- FDA GRN 580 inventory — INNOBIO H. pluvialis extract in specified foods; no questions on 18 December 2015. Complete archived response was not recovered; inventory and GRN 700 footnote support this narrow status.
- Nutritional Outlook AstaReal NDI reporting — Historical attributed 12 mg/day correspondence report. Specific original FDA response not recovered; no universal dose/approval certificate.
- Shah 2016 production review — Historical chemistry/production background. NSFC, Shenzhen, State Oceanic Administration and Thousand People Plan support; no commercial/financial relationships declared. Not a current market census.
- Adiguzel/Ülger 2024 neurodegeneration review — Identity and abstract verified; complete original Methods/Results/financial declarations not recovered. Not used here as proof of clinical benefit or safety.
- Castillo 2023 wet-algae pancake experiment — Original composition/food study, not a human trial. Xunta/FEDER, FCT and Spanish support disclosed, with no known competing interests; product contribution terms and full backing not itemised.
- 2025 krill-oil narrative review — Selected composition/background/declarations read; no funding or conflicts declared. Not isolated-pigment efficacy, per-serving market survey or clearance of every underlying original.
- Ito 2018 UV-response trial — FUJIFILM sponsor/funder and three employee authors; 23 randomized, 22 analysed. Also see Liu 2026 exercise review: reports outcome-specific signals with mixed protocols/internal reporting limits, joint-laboratory and other grant support; no competing interests declared.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.